Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics


Iovance Biotherapeutics, Inc. (IOVA): $7.96

0.01 (+0.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IOVA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IOVA Stock Price Chart Interactive Chart >

Price chart for IOVA

IOVA Price/Volume Stats

Current price $7.96 52-week high $18.73
Prev. close $7.95 52-week low $5.42
Day low $7.90 Volume 4,476,743
Day high $8.19 Avg. volume 5,241,885
50-day MA $6.62 Dividend yield N/A
200-day MA $10.11 Market Cap 1.26B

Iovance Biotherapeutics, Inc. (IOVA) Company Bio


Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.


IOVA Latest News Stream


Event/Time News Detail
Loading, please wait...

IOVA Latest Social Stream


Loading social stream, please wait...

View Full IOVA Social Stream

Latest IOVA News From Around the Web

Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.

Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock a better investment at this time?

Currently, Iovance Biotherapeutics Inc.’s (IOVA) stock is trading at $7.34, marking a gain of 4.93% from last night’s close. At this price, the stock is -60.78% below its 52-week high of $18.73 and 35.52% above its 52-week low of $5.42. Based on the past 30-day period, the stock price is -0.34% below the high and […]

US Post News | January 24, 2023

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

Yahoo | January 24, 2023

Iovance Biotherapeutics Acquires Clinigen''s IL-2 Product For Upfront £166.7M

Full story available on Benzinga.com

Benzinga | January 23, 2023

Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million

23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties Clinigen Limited (‘Clinigen'') (‘the Company''), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) (‘Iovance''), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)). Terms of the agreement include an upfront payment of £166.7 million, a £41.7 million milestone payment upon first approval of lifileucel in advanced melanoma, and double-digit Proleukin® global sales r...

Benzinga | January 23, 2023

Foolproof stocks: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA 5.90%), QuantumScape Corporation (NYSE:QS 3.36%)

IOVA has seen its SMA50 which is now -0.22%. In looking the SMA 200 we see that the stock has seen a -36.45%. QS has seen its SMA50 which is … The post Foolproof stocks: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA 5.90%), QuantumScape Corporation (NYSE:QS 3.36%) appeared first on Stocks Equity .

Stock Equity | January 23, 2023

Read More 'IOVA' Stories Here

IOVA Price Returns

1-mo 24.57%
3-mo -10.56%
6-mo -36.52%
1-year -52.19%
3-year -63.39%
5-year -51.76%
YTD 24.57%
2022 -66.53%
2021 -58.86%
2020 67.63%
2019 212.77%
2018 10.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7184 seconds.